0.00Open0.80Pre Close0 Volume485 Open Interest230.00Strike Price0.00Turnover2453.08%IV17.78%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier-7DDays to Expiry0.80Extrinsic Value100Contract SizeAmericanOptions Type-0.1126Delta0.0134Gamma348.45Leverage Ratio-662.3991Theta0.0000Rho-39.25Eff Leverage0.0011Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet